Cipla's Q3FY26 performance saw flat revenue at INR 7,074 Cr, but profit (PAT) dipped 57% YoY to INR 676 Cr, with EBITDA also down significantly to INR 1,255 Cr.

India business was a bright spot, growing strong double-digits, fueled by respiratory outperformance and strategic moves.

Cipla inked a deal to exclusively market Pfizer's key brands in India and acquired Inzpera Healthsciences for its paediatric portfolio, boosting market presence.

In North America, Albuterol maintains its #1 spot with a 22% market share.

However, Lanreotide supply faces temporary interruption, expected to resume H1 FY27. Upcoming pipeline launches, including 4 respiratory (like gAdvair) and 4 peptide products by FY27, are key growth drivers.

The company also launched India’s first Lung Diagnostics & Wellness Center in Delhi.

Financially, despite the profit dip, Cipla maintains a robust balance sheet with Net Cash of INR 10,229 Cr.

Management's outlook highlights continued focus on India market expansion, consumer wellness growth, and a strong product pipeline to drive future performance.